Additional long-term follow-up is needed to confirm this treatment. With a low complication rate and satisfactory bDFS rates, this combination therapy can be considered an alternative method for clinical Stage T1c-T3b prostate cancer and is expected to improve patient quality of life. Acute toxicity was mild to moderate (Radiation Therapy Oncology Group grade 1-2) and consisted of cystourethritis or proctitis in 29 (29.6%) of 98 patients. This time, discussing the radioisotope, Iridium-192.Work cited page located here. The 2-year and 5-year bDFS rate was better in patients with an initial prostate-specific antigen level of less than 20 ng/mL compared with 20 ng/mL or greater (98.6% and 97.1% versus 93.1% and 82.8%, respectively, P = 0.0261). The bDFS rate by T stage was 98.6% at 2 years and 95.9% at 5 years for Stage T1c-T2b and 88.0% and 84.0% for Stage T3a-b, respectively (P = 0.047). The overall biochemical disease-free survival (bDFS) rate was 95.9% at 2 years and 92.9% at 5 years. ![]() Seven patients (7.1%) developed recurrence and treatment was considered a failure (bone metastasis in two and biochemical failure in five). Ir192 has a spectrum of 6 possible energies, ranging from 200 Kev to 600 Kev. Electron capture is responsible for the remaining 4 of Ir192 decays. Some of the particles are captured by other Ir192 nuclei, which are then converted to Os192. The most recent prostate-specific antigen level was 0.0 to 3.9 ng/mL (median 0.4). About 96 of Ir192 decays occur via emission of (beta) and (gamma) radiation, leading to Pr192. No patient received adjuvant hormonal therapy after RT. Treatment consisted of external beam RT (four ports) to the prostate of 16 fractions of 2.3 Gy to a total dose of 36.8 Gy and high-dose-rate brachytherapy of 4 fractions of 6.0 Gy within 30 hours to a total dose of 24.0 Gy. Included in the study were 98 patients with T1c-T3bN0M0 prostate cancer who were diagnosed between October 1997 and September 2002 and underwent high-dose-rate brachytherapy with external beam RT. ![]() This leads to a complex decay pattern resulting in 29 gamma emission peaks from 0.110 to 1.378 MeV, various characteristic x-rays, and numerous electrons up to 1.377 MeV. To determine the efficacy of radiotherapy (RT) for T1c-T3bN0M0 prostate cancer in a prospective clinical trial of concurrent external beam RT and fractionated iridium-192 high-dose-rate brachytherapy. What happens when iridium-192 decays Ir decays into platinum 192 (192Pt) via decay 95.1 of the time and the remaining 4.9 in osmium 192 (192Os) by EC.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |